Document Detail

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.
MedLine Citation:
PMID:  16368054     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: This study was designed to compare the efficacy, safety and tolerability of rosiglitazone (RSG) added to submaximal doses of metformin (MET) with dose escalation to the maximal effective dose of MET monotherapy in type 2 diabetes mellitus. RESEARCH DESIGN AND METHODS: In this multi-center, double-blind, randomized, parallel-group study, 766 subjects with a baseline MET dose of 1000 mg/day were randomized to receive either RSG 4 mg/day (4 mg/1000 mg) or MET 500 mg/day (1500 mg/day total dose) for 8 weeks. Only the RSG dose was increased in the combination group - to 8 mg/day (8 mg/1000 mg) - and only the MET dose was increased in the MET monotherapy group - to 2000 mg/day for the remaining 16 weeks. RESULTS: After 24 weeks, RSG added to MET (8 mg/1000 mg/day) was at least as effective as 2000 mg/day of MET in improving HbA(1c), with mean reductions of -0.93% (95% CI: -1.06%, -0.80%) and -0.71% (95% CI: -0.83%, -0.60%), respectively, from baseline in subjects that completed the study according to the investigator (mean treatment effect/difference of -0.20% [95% CI: -0.36%, -0.04%]). In addition, a higher percentage of subjects in the RSG + MET group achieved American Diabetes Association target levels of HbA(1c) < 7% (58.1% versus 48.4%) and American Association of Clinical Endocrinologists target levels of HbA(1c) <or= 6.5% (40.9% versus 28.2%). This combination provided significantly greater reductions from baseline in fasting plasma glucose (FPG; -2.29 mmol/L [+/- 2.37 mmol/L] and -1.12 mmol/L [+/- 2.41 mmol/L], respectively), with a treatment difference of -0.85 mmol/L (95% Cl: -1.23 mmol/L, -0.47 mmol/L). For the intent-to-treat (ITT) population, the percentage of subjects experiencing a gastrointestinal side-effect was 27.9% and 38.7% for the RSG + MET and MET groups, respectively (OR = 1.63, 95% CI: 1.19, 2.24). Mean body weight (+/- SD) increased in all randomized subjects treated with the combination therapy (+ 1.79 +/- 4.15 kg) compared with a mean weight loss in the up-titrated MET group (-1.78 +/- 3.50 kg). CONCLUSIONS: This study suggests that addition of RSG to submaximal doses of MET may be a suitable alternative to the maximal effective dose of MET monotherapy.
P Weissman; B J Goldstein; J Rosenstock; B Waterhouse; A R Cobitz; M J Wooddell; L J Strow
Related Documents :
16331754 - A phase 2 dose-finding study of pegylated recombinant methionyl human soluble tumor nec...
19637334 - Fontolizumab in moderate to severe crohn's disease: a phase 2, randomized, double-blind...
2725884 - A double-blind, placebo-controlled, dose-ranging study to investigate the safety and ef...
2574594 - Failure of terfenadine in relieving the pruritus of atopic dermatitis.
18634214 - Diagnosis and treatment of sarcocystis neurona in a captive harbor seal (phoca vitulina).
2439844 - Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrilla...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current medical research and opinion     Volume:  21     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-21     Completed Date:  2006-02-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2029-35     Citation Subset:  IM    
Medicine and Endocrinology, University of Miami School of Medicine, Miami, FL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / analysis
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Diabetes Mellitus, Type 2 / drug therapy*
Double-Blind Method
Drug Therapy, Combination
Gastrointestinal Tract / drug effects
Metformin / administration & dosage*
Middle Aged
Thiazolidinediones / administration & dosage*
Reg. No./Substance:
0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Thiazolidinediones; 122320-73-4/rosiglitazone; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The economic burden of schizophrenia in Canada in 2004.
Next Document:  Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in pa...